en · de · es · fr · pt
cjc-1295-notes.peptides1004.com › Topic › Cjc-1295 Structure And Mechanism — Reference Sheet

Cjc-1295 Structure And Mechanism — Reference Sheet

By Editorial Desk · published 2025-09-07 · last reviewed 2025-09-22 · Topic

Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-09-22. Where a claim depends on a specific study, the study is described rather than over-claimed.

CJC-1295 Structure And Mechanism

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

Analytical Measurement And Stability

Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.

Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.

Cjc-1295 at a glance

PropertyValueNotes
Physical formLyophilized white powderSupplied as a freeze-dried solid for research use
Molecular weightApproximately 3,647 Da (DAC form)Lower for the variant lacking the albumin-binding moiety
SolubilitySoluble in water and aqueous bufferTypically dissolved in sterile or bacteriostatic water
Typical storage temperature−20 °C or belowDry powder, desiccated and protected from light
Common analytical methodReversed-phase HPLC with mass spectrometryUsed for purity estimation and identity confirmation

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Related pages on this site

Background and Molecular Features

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Supporting material

As of 2023, Thermos and THERMOS remain a registered trademark in some countries, including the United States, but the lowercase "thermos" was declared a genericized trademark by court action in the United States in 1963.

Also in March 2002, CJTF-180 took over command and control of SOF forces in Afghanistan. On May 19, a Green Beret from Support Company, 2nd Battalion, 19th SFG, was killed while on patrol in Paktita. Later in 2002, CJSOFT became a single integrated command under the broader CJTF-180 that commanded all US forces assigned to OEF-A, it was built around an Army Special Forces Group (often composed of National Guard units) and SEAL teams, in September 2002, the 20th SFG and 2nd Battalion 7th SFG has assumed the role of CJSOTF-Afghanistan allowing the 3rd SFG to be part of the invasion of Iraq. Until the arrival of General Stanley McChrystal in 2009, counterinsurgency was focused on Direct Action against insurgents on a localised level and often led by Green Beret teams, who were also recruiting and training Afghan Militia Forces to provide security in their area of operations. The ODAs were assigned either an offensive or Direct Action role which would have them operation in far-flung provinces with locally recruited militia, or they would be assigned to an FID (Foreign Internal Defence) detail which saw them partnered with Afghan Army battalions in a training and mentoring role. In 2007, the Green Berets FID role succeeded in creating the first two Afghan Commando units. Green Beret ODAs often worked closely with the Romanian special forces, they took part in joint patrols, deploying hybrid ODAs of both Romanian and American soldiers. On January 25, 2008, a small element of U.S.

13B Cannon Crewmember 13E Fire Direction Specialist (Cannon Artillery) Later consolidated into 13B 13F Fire Support Specialist 13J Fire Control Specialist (Formerly 13P and 13D) 13M Multiple Launch Rocket System/High Mobility Artillery Rocket System Crewmember 13R Field Artillery Firefinder Radar Operator 13T Field Artillery Surveyor/Meteorological Crewmember 13U Field Artillery Recruit 13Z Field Artillery Senior Sergeant/Sergeant Major

=== Chemi-ionization === Chemi-ionization is the formation of an ion through the reaction of a gas phase atom or molecule with an atom or molecule in an excited state. Chemi-ionization can be represented by

==== Pharmacokinetics of pyridine derivatives ==== Axitinib has short half-life, ranging from 2.5 to 6.1 hours, and therefore steady state should be reached in 2–3 days after the first dose. Peak plasma concentration is reached in 2.5 to 4.1 hours. In vitro protein binding is over 99%. Axitinib is primarily metabolized in the liver by CYP3A4/5. 30-60% of the drug is excreted in faeces, and about 23% in urine. Regorafenib is a pyridine derivative, but also a urea derivative and has therefore been covered in that section.

Sources: en.wikipedia.org

Supporting material

Agribusiness Arla Foods (dairy) Dansk Landbrugs Grovvareselskab (DLG) (agricultural coop (Danish a.m.b.a.). Main focus is agricultural supply and trade) Danish Crown (meat products) Banking Danske Bank (commercial banking and mortgage lending) Nordea Nykredit Jyske Bank Saxo Bank Sydbank Clothing and attire ECCO (shoe and leather accessories manufacturer and retailer) Bestseller Construction FLSmidth (global supplier of equipment and services to the cement and minerals industries) Rockwool (mineral wool producer with production in 28 countries) Velux (windows and skylights production, owned by Villum Foundation) Rambøll COWI Energy technology Vestas (wind turbines) Siemens Wind Power (wind turbines) Danfoss (climate and energy) Grundfos (the world's largest pump manufacturer) NKT A/S (Power cables and subsea umbilicals) Ørsted (company) (Formerly known as DONG energy) Electronics Linak Bang and Olufsen (hi-fi equipment) Nilfisk Ortofon Danfoss Food and drink Carlsberg (brewing company) Royal Unibrew Novonesis (food ingredients and enzymes) Danisco (enzymes, biotechnology and pharmaceutical supplier) Insurance Alm. Brand Tryg Medical equipment Widex William Demant Pharmaceutical and biotechnology Many of the largest food producers are also engaged in biotechnology and research. Notable companies dedicated to the pharmaceutical and biotechnology sector, includes:

=== Dental === Silanization is often used to treat ceramics used for dental restorations and repairs. Applying silane coupling agents after grit blasting the ceramic material has been shown to produce durable resin bonding. Additionally, for titanium and other metal implant features in wires and crowns, application of silane coupling agents followed by resin composite cement has produced durable bonding in a clinical application. While silane coupling agents are widely used in dental practices, they are subject to bond degradation due to the environment of the oral cavity, weakening the adhesion between the surfaces that they are used to connect.

=== Sustained release === There are several methods by which tablets and capsules can be modified in order to allow for sustained release of the active compound as it passes through the digestive tract. One of the most common methods is to embed the active ingredient in an insoluble porous matrix, such that the dissolving drug must make its way out of the matrix before it can be absorbed. In other sustained release formulations the matrix swells to form a gel through which the drug exits. Another method by which sustained release is achieved is through an osmotic controlled-release oral delivery system, where the active compound is encased in a water-permeable membrane with a laser drilled hole at one end. As water passes through the membrane the drug is pushed out through the hole and into the digestive tract where it can be absorbed.

Microarrays can also be used for detecting autoantibodies, utilizing autoantigen arrays to screen against many antigens or potential antigens in parallel. Treatment development involves the development of antigen-specific therapies for autoimmunity, cancer and allergies; the identification of small molecule targets that could potentially be used as new drugs.

Sources: en.wikipedia.org

Supporting material

==== Initial loans ==== Townsend entered the senior Tottenham team under manager Harry Redknapp. In August 2009, he went on a month's loan to League One club Leyton Orient, extended at the end of the month to the end of December, after which he returned to Tottenham. In 26 appearances for Orient, Townsend scored twice, including a "great goal" in a 3–3 draw against Yeovil, passing three opposing players with a run that began in his own half, leading the opposition manager to lament that his players had not been more ruthless and taken him down with a professional foul. Having not yet made his Tottenham debut, on 14 January 2010, Townsend was again taken on loan by a League One club, Milton Keynes Dons, until the end of the season, although he was recalled after just two months due to injuries. In nine matches for the Dons he had scored twice. The season ended without Townsend having made his debut for Tottenham. On 12 August 2010, Townsend signed another season-long loan, moving up to the Championship level with Ipswich Town, but this was terminated on 20 December, as Redknapp believed he had not been playing regularly enough. He had played 16 times, scoring once.

== Treatment == There is no clearly defined cure for necrobiosis. NLD may be treated with PUVA therapyPhotodynamic therapy and improved therapeutic control. Although some techniques can be used to diminish the signs of necrobiosis, such as low-dose aspirin orally, a steroid cream or injection into the affected area, this process may be effective for only a small percentage of those treated. First medications applied are topical corticosteroids, but these may not be effective for all patients. Compression therapy and proper wound care are essential for treatment. Anti-inflammatory, immunosuppressive, and immunomodulatory agents like chloroquine, dapsone, and oral calcineurin inhibitors. These target the cyclic and damaging immune response occurring in NL. Since TNF is essential to granuloma formation, antibodies that bind to TNF-α to prevent its action help reduce inflammation, pain, and the growth of ulcers. A study found a 70% complete reduction of NL when using TNF-α inhibitors. Hyperbaric oxygen can also be used to increase the amount of oxygen circulation and promote wound healing.

=== France === In 2010 the French government allocated €651.6 million to the Commissariat à l'énergie atomique to finalize the design of ASTRID (Advanced Sodium Technological Reactor for Industrial Demonstration), a 600 MW fourth-generation reactor design to be finalized in 2020. As of 2013 the UK had shown interest in the PRISM reactor and was working in concert with France to develop ASTRID. In 2019, CEA announced this design would not be built before mid-century.

The official short title of the bill; A ban on pharmacy benefit managers using spread pricing; A ban on the use of federal funds in Medicaid, the Children's Health Insurance Program (CHIP) and the Affordable Care Act from being used to pay for gender-affirming care for adults and children (the Crenshaw Amendment) starting in 2027; Changes to the Medicaid funding formula to increase benefits for Alaska and Hawaii; An expansion of Pell Grants to cover workforce-training programs (the parliamentarian approved a modified version); Requiring states that use their own funds to offer health insurance for illegal immigrants to pay a higher Medicaid funding; Limitations on the pandemic-era employee retention tax credit; $2 billion allocated for Pentagon military intelligence programs and $500 million allocated for missile development; A policy that would have ended SNAP assistance for some households that are also eligible for other assistance; and A provision to allow mining around the Boundary Waters wilderness.

In August 2026, Disney and TikTok announced a content-sharing partnership that will allow participating TikTok creators to use approved material from Disney films and television programs in their videos. Selected creator videos will also be featured within Disney+ through its Verts mobile video section. The initiative includes content related to Disney properties such as Marvel, Star Wars, Pixar, and FX, and is expected to begin as a pilot in the United States before potentially expanding to other markets.

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 differ from modified GRF(1-29)?

The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.

Is CJC-1295 an approved medicine?

It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.

What is known about its half-life?

Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.

How are the two variants distinguished in a laboratory?

The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.

Network